Business, energy, technology, markets and global industry news from Business News Today

schizophrenia

PharmaDeviceNews schizophrenia
Pharma & Biotech

Does MapLight Therapeutics, Inc. have the clinical design to compete in crowded neuropsychiatric markets?

MapLight Therapeutics nears key Phase 2 data in schizophrenia and autism. Discover how its trial design could shape CNS market competition.

Read More
Representative image: A blood-based mRNA biomarker test could mark a turning point for objective psychiatric diagnostics as Laguna Diagnostics advances its FDA breakthrough-designated tool to help clinicians differentiate schizophrenia from bipolar I disorder.
Medical Devices & Diagnostics

Why the FDA breakthrough pathway matters for Laguna Diagnostics’ psychiatric test

Psychiatry needs objective diagnostics. Laguna Diagnostics now faces the harder test: proving mRNA biomarkers can scale in real care.

Read More
Representative image of a clinical consultation on long-term schizophrenia care, as Johnson & Johnson’s CAPLYTA FDA label update sharpens focus on relapse prevention, treatment stability, and durability in neuropsychiatric therapy.
Pharma & Biotech

Johnson & Johnson’s CAPLYTA update raises the bar for long-term schizophrenia stability

Schizophrenia drugs face a durability test. CAPLYTA’s FDA update gives Johnson & Johnson a stronger long-term stability story.

Read More
Features & Analysis

Can Teva Pharmaceutical Industries Ltd.’s Home Ground platform reshape schizophrenia support beyond medication?

Read how Teva Pharmaceutical Industries Ltd.’s Home Ground may reshape schizophrenia support, adherence, and care pathways. Discover what changes next.

Read More
Pharma & Biotech

What Alto Neuroscience’s ALTO-101 setback reveals about the difficulty of treating cognitive impairment in schizophrenia

Alto Neuroscience’s ALTO-101 missed in Phase 2. Read what the setback means for schizophrenia cognition, partnering prospects, and ALTO-207 next.

Read More
Vanda Pharmaceuticals secures milsaperidone approval, but bipolar I disorder and schizophrenia uptake remains uncertain
Pharma & Biotech

FDA approval of milsaperidone puts Vanda Pharmaceuticals into crowded bipolar I disorder and schizophrenia markets

FDA approves milsaperidone for bipolar I disorder and schizophrenia. Explore what this means for psychiatry, competition, and Vanda Pharmaceuticals’ strategy.

Read More
Representative image of pharmaceutical tablets and clinical tools, reflecting ongoing advancements in adjunctive therapies like CAPLYTA (lumateperone) for major depressive disorder.
Pharma & Biotech

Can J&J’s lumateperone raise the bar for MDD remission? New CAPLYTA data fuels fresh hope

Johnson & Johnson (J&J) has presented new pooled data from Phase 3 clinical trials showing that CAPLYTA (lumateperone), used as an adjunctive therapy with antidepressants, significantly improved remission rates in adults with major depressive disorder compared to placebo. The results, highlighted at the 64th Annual Meeting of the American College of Neuropsychopharmacology, indicate nearly double

Read More
Pharma & Biotech

NMPA clears Zai Lab’s COBENFY, rewriting the schizophrenia treatment playbook

Zai Lab’s COBENFY approved in China as a first-in-class schizophrenia treatment. Find out what this milestone means for psychiatry and pharma innovation.

Read More